Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Study to Assess the Efficacy and Safety of Olaparib Versus Enzalutamide or Abiraterone Acetate in Chinese Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations (PROfound-CN)

NCT05457257 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05457257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05457257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Study to Assess the Efficacy and Safety of Olaparib Versus Enzalutamide or Abiraterone Acetate in Chinese Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations (PROfound-CN)
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Active, not recruiting
Start date
July 29, 2022
Completion date
December 31, 2026
Enrollment
43 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer